H.C. Wainwright Remains a Buy on Tearlab Corp

By Carrie Williams

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Tearlab Corp (NASDAQ: TEAR), with a price target of $4. The company’s shares closed yesterday at $2.60, close to its 52-week low of $1.85.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -6.2% and a 36.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Stemline Therapeutics Inc.

Tearlab Corp has an analyst consensus of Strong Buy, with a price target consensus of $5.63.

The company has a one year high of $9 and a one year low of $1.85. Currently, Tearlab Corp has an average volume of 180.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TearLab Corp. engages in the development and marketing of lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by testing disease markers in tears at the point-of-care. It also intends to measure the osmolarity of human tears to aid in the diagnosis of dry eye disease in patients suspected of having dry eye disease. The company was founded by Benjamin D. Sullivan in 1996 and is headquartered in San Diego, CA.